The diabetic foot: Attention, danger!;Le pied du diabétique: Attention, danger!

Annales de Dermatologie et de Venereologie

Volumn 132, Issue 10 I, 2005, Pages 797-814

  Ferreira Maldent, N ^a   Maillot, F ^b   Guilmot, J L ^a  

^a CHU BRETONNEAU   (France)

^b Service de Médecine Interne   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFALEXIN; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; CLOPIDOGREL; COTRIMOXAZOLE; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; SULTAMICILLIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTERIOGRAPHY; ARTERIOSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; CLINICAL EXAMINATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DEBRIDEMENT; DIABETES CONTROL; DIABETIC ANGIOPATHY; DIABETIC FOOT; DIABETIC MICROANGIOPATHY; DIABETIC NEUROPATHY; DIET; DISEASE CLASSIFICATION; DOPPLER ECHOGRAPHY; DYSLIPIDEMIA; FOOT AMPUTATION; HUMAN; HYGIENE; MAGNETIC RESONANCE ANGIOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PODIATRY; PREVALENCE; PROGNOSIS; SCAR FORMATION; SMOKING;

EID: 27644583674     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0151-9638(05)79448-5     Document Type: Article

References (72)

1. Rayman G, Krishnan ST, Baker NR, Wareham AM, Rayman A. Are we underestimating diabetes-related lower-extremity amputation rates? Results and benefits of the first prospective study. Diabetes Care 2004;27:1892-6.
2. Levin ME, O'Neal LW, eds. The diabetic foot (4th edition). St Louis: CV Mosby 1988.
3. Llorca V, Bornot C, Grandperret S, Winiszewsky P, Jeunet L, Tschudnowski M. Incidence des amputations chez les diabétiques en Franche Comté, en 2001. Diabetes Metab 2002;28 (suppl):1542.
4. Van Damme H, Rorive M, Martens De Noorthout BM, Quaniers J, Scheen A, et al. Amputations in diabetic patients: a plea for footsparing surgery. Acta Chir Belg 2001;101:123-9.
5. Apelqvist J. Long term prognosis for diabetic patients with foot ulcers. J Intern Med 1993;233:485-91.
6. Most RS, Sinnock P. The epidemiology of lower extremity amputations in diabetic individuals. Diabetes Care 1983;6:87-91.
7. Beressi JP, Cottez ML, Fichelle JM, Larger E, Bouteleux JF, Vexiau P. Coût des lésions chez le patient diabétique: étude rétrospective de 10 mois dans un centre hospitalier universitaire. Diabet Metab 1999;25 (suppl 1):LVI.
8. Lundbaek K. Blood vessel disease. Acta Diabetol 1971;8:3-4.
9. Capron L, Wyplosz B. Athérosclérose: description, mécanismes et étiologie. Encycl Méd Chir (Elsevier, Paris) Angiologie, 19-0090, 1999, 10 p.
10. Andresen JL, Rasmussen LM, Ledet T. Diabetic macroangiopathy and atherosclerosis. Diabetes 1996;45 (suppl. 3):S91-4.
11. Vlassara H, Bucala R. Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes 1996;45:S65-6.
12. Jörneskog G, Brismar K, Fagrell B. Skin capillary circulation severely impaired in toes of patients with IDDM, with and without late diabetic complications. Diabetologia 1995;38:474-80.
13. Sumpio BE. Foot ulcers. N Engl J Med 2000;343:787-93.
14. Lavery LA, Armstrong DG, Vela SA, Quebedeaux TL, Fleischli JG. Practical criteria for screening patients at high risk for diabetic foot ulceration. Arch Intern Med 1998;158:157-62.
15. Mason J, O'Keeffe C, McIntosh A, Hutchinson A, Booth A, Young RJ. A systematic review of foot ulcer in patients with type 2 diabetes mellitus. Diab Med 1999;16:889-909.
16. Boulton AJM, Kirsner RS, Vileikyte L. Neuropathic diabetic foot ulcers. N Engl J Med 2004;351:48-55.
17. Frykberg RG, Mendeszoon E. Management of the diabetic Charcot foot. Diabetes Metab Res Rev 2000;16 (Suppl 1):S59-S65.
18. McNeely MJ, Boyko EJ, Ahroni JH, Stensel VL, Reiber GE, Smith DG, et al. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. How great are the risks? Diabetes Care 1995;18:216-19.
19. Fernando DJ, Masson EA, Veves A, Boulton AJ. Relationship of limited joint mobility to abnormal foot pressures and diabetic foot ulceration. Diabetes Care 1991;14:8-11.
20. Delbridge L, Perry P, Marr S, Arnold N, Yue DK, Turtle JR, et al. Limited joint mobility in the diabetic foot: relationship to neuropathic. Diabet Med 1988;5:333-7.
21. Mueller MJ, Diamond JE, Delitto A, Sinacore DR. Insensitivity, limited joint mobility, and plantar ulcers in patients with diabetes mellitus. Phys Ther 1989;69:453-9; discussion 459-62.
22. Lavery LA, Lavery DC, Quebedeax-Farnham TL. Increased foot pressures after great toe amputation in diabetes. Diabetes Care 1995;18:1460-2.
23. Wagner FW. The diabetic foot. Orthopedics 1987;10:163-72.
24. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. Diabetes Care 1998;21:855-59.
25. Lipsky BA. International consensus group on diagnosing and treating the infected diabetic foot. A report from the international consensus on diagnosing and treating the infected foot. Diabetes Metab Res Rev 2004;16 (Suppl 1):S68-S77.
26. Grayson ML, Gibbons GW, Balogh K, Levin E, Karchmer AW. Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. JAMA 1995;273:721-3.
27. Lipsky BA. Medical treatment of diabetic foot infections. Clin Infect Dis 2004;39 Suppl 2:S104-14.
28. Eneroth M, Apelqvist J, Stentström A. Clinical characteristics and outcome in 223 diabetic patients with deep foot infections. Foot Ankle Int 1997;18 716-22.
29. International Working Group on the Diabetic Foot. International consensus on the diabetic foot [CD-ROM]. Brussels: International Diabetes Foundation, May 2003.
30. Breen JD, Karchmer AW. Staphylococcus aureus infections in diabetic patients. Infect Dis Clin North Am 1995;9:11-24.
31. Lipsky BA. Clin Infect Dis 1997;25:1318-26.
32. Tuomilehto J, Lindstrom J, Erikson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Finnish diabetes prevention study group: prevention of type 2 diabetes mellitus by changes in life style among subject with impaired glucose tolerance. N Engl J Med. 2001;344:1343-50.
33. Charbonnel B, Bouhanick B, Le Feuvre C et le Groupe de Travail. Recommandations SFC/ALFEDIAM sur la prise en charge du patient diabétique vue par le cardiologue. Arch Mal Ciœur Vx. 2004;97:229-49.
34. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction of the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
35. McFarlane SI, Jacober SJ, Winer N, Kaur J, Castro JP, Wui MA, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002;25: 718-23.
36. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9
37. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 Diabetes. UKPDS 39. BMJ. 1998;317:713-20
38. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.
39. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 Diabetes. UKPDS 39. BMJ 1998;317:713-20.
40. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-9.
41. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
42. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Lancet 2004;364:685-96.
43. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pederden O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:3
44. Apelqvist J, Bakker K, van Houtum WH, Nabuurs-Franssen MH, Schaper NC. International consensus and practical guidelines on the management and the prevention of the diabetic foot. International Working Group on the Diabetic Foot. Diabetes Metab Res Rev 2000;16 (Suppl 1):S84-S92.
45. Cavanagh PR, Ulbrecht JS, Caputo GM. The biomechanics of the foot in diabetes mellitus. In: The Diabetic Foot (6th ed.). Bowker JH, Pfeifer MA, eds Saint Louis: Mosby. 2001:125-96.
46. Armstrong DG, Lavery LA, Nixon BP, Boulton AJ. It's not what you put on, but what you take off: techniques for debriding and off-loading the diabetic foot wound. Clin Infect Dis 2004;39 (suppl2):S92-S99.
47. Caravaggi C, Faglia E, De Giglio R, Mantero M, Quarantiello A, Sommariva E, et al. Effectiveness and safety of a nonremovable fiberglass off-bearing cast versus a therapeutic shoe in the treatment of neuropathic foot ulcers: a randomized study. Diabetes care 2000;23:1746-51.
48. Steed DL, Donohoe D, Webster MW, Lindsley L. Diabetic Ulcer Study Group. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. J Am Coll Surg 1996;183:61-4.
49. Smiell JM. Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Studies Group. J Surg 1998;176 (suppl 2A):68S-73S.
50. Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care 1999;22:692-5.
51. Reed AB, Conte MS, Donaldson MC, Mannick JA, Whittemore AD, Belkin M. The impact of patient age and aortic size on the results of aortobifemoral bypass grafting. J Vasc Surg 2003;37:1219-25.
52. Defraigne JO, Vazquez C, Limet R. Crossover iliofemoral bypass grafting for treatment of unilateral iliac atherosclerotic disease. J Vasc Surg 1999;30:693-700.
53. Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology 1997;204:87-96.
54. Hamdan AD, Saltzberg SS, Sheahan M, Froelich J, Akbari CM, Campbell DR, et al. Lack of association of diabetes with increased postoperative mortality and cardiac morbidity: results of 6565 major vascular operations. Arch Surg 2002;137:417-21.
55. Clark TW, Groffsky JL, Soulen MC. Predictors of long-term patency after femoropopliteal angioplasty: results from the STAR registry. J Vasc Interv Radiol 2001;12:923-33.
56. Pomposelli FB, Kansal N, Hamdan AD, Belfield A, Sheahan M, Campbell DR, et al. A decade of experience with dorsalis pedis artery bypass: analysis of outcome in more than 1000 cases. J Vasc Surg 2003;37:307-15.
57. American Diabetes Association. Peripheral arterial disease in people with diabetes.Diabetes Care 2003;26:3333-41.
58. Duthois S, Cailleux N, Benosman B, Levesque H. Tolerance of Iloprost and results of treatment of chronic severe lower limb ischaemia in diabetic patients. A retrospective study of 64 consecutive cases Diabetes Metab 2003;29:36-43.
59. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004;39:885-910.
60. Van der Meer JW, Koopmans PP, Lutterman JA. Antibiotic therapy in diabetic foot infection. Diabet Med 1996;13 (Suppl 1):S48-S51.
61. Van Baal JC. Surgical treatment of the infected diabetic foot. Clin Infect Dis 2004;39 (suppl 2):S123.
62. Lepantalo M, Biancari F, Tukiainen E. Never amputate without consultation of a vascular surgeon. Diabetes Metab Res Rev 2000;16 (suppl 1): S27-32.
63. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al. Diagnosis and treatment of diabetic foot infections Clin Infect Dis 2004;39:885-910.
64. Grayson ML. Diabetic foot infections: antimicrobial therapy. Infect Dis Clin North Am 1995;9:143-61.
65. International Working Group of the Diabetic Foot. International consensus on the diabetic foot. Amsterdam, 1999:1-96.
66. Dahmen R, Haspels R, Koomen B, Hoeksma AF. Therapeutic footwear for the neuropathic foot: an algorithm. Diabetes Care 2001;24:705-9.
67. Jude EB, Selby PL, Burgess J, Lilleystone P, Mawer EB, Page SR, et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 2001;44: 2032-7.
68. Holstein P, Ellitsgaard N, Olsen BB, Ellitsgaard V. Decreasing incidence of major amputations in people with diabetes. Diabetologia 2000;43:844-7.
69. van Houtum WH, Rauwerda JA, Ruwaard D, Schaper NC, Bakker K. Reduction in diabetes-related lower-extremity amputations in The Netherlands: 1991-2000. Diabetes Care 2004;27:1042-6.
70. Patout CA Jr, Birke JA, Horswell R, Williams D, Cerise FP. Effectiveness of a comprehensive diabetes lower-extremity amputation prevention program in a predominantly low-income African-American population. Diabetes Care;23:1339-42.
71. Larsson J, Apelqvist J, Agardh CD, Stenstrom A. Decreasing incidence of major amputation in diabetic patients: a consequence of a multidisciplinary foot care team approach? Diab Med 1995;12:770-6.
72. Apelqvist J, Larsson J. What is the most effective way to reduce incidence of amputation in the diabetic foot? Diabetes Metab Res Rev 2000;16 (suppl 1):S75-S83.